Abstract
Lobular in situ neoplasia (LISN) is encountered with increasing frequency in core needle biopsies (CNB) of the breast. It is a generalised risk factor and probable nonobligate precursor for some breast cancers. Historically, open biopsy was performed to exclude associated malignancy. Controversy currently surrounds the management of LISN, and practice consequently varies between departments. This study is a review of a single centre's 13-year experience of managing LISN with vacuum-assisted biopsy (VAB) in order to assess the safety of this policy.
Highlights
Previous research in this centre enabled the introduction of a local protocol of nonbiopsy and discharge of women
Mammography-detected cancers were luminal in 77% (P = 0.03), node negative in 77% (P = 0.005), with ductal carcinoma in situ (DCIS) in 81% (P = 0.007)
We applied our approach to 13 experienced readers assessing 13,694 screening mammograms from a large clinical study where women are categorised as high risk if they have a 5 to 8% 10-year risk computed by a validated risk model and their breast density is in the top decile of the study population
Summary
Previous research in this centre enabled the introduction of a local protocol of nonbiopsy and discharge of women
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
